US › Healthcare

Fulcrum Therapeutics Inc (FULC)

US · Healthcare · Biotechnology

$3.80+2.43%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-26.2M
Profit YoY
-51.4%
EPS
$-0.29
EPS estimate
$-0.21

EPS came in at -0.29 against a street estimate of -0.21 — a miss of 36.5%.

Key statistics

Market cap
$273.1M
Forward P/E
0.0
P/B
0.88
Book value
$4.07
EPS (TTM)
$-1.21
52-week high
$15.74
52-week low
$2.83
50-day MA
$4.10
200-day MA
$7.95
Beta
3.00

Analyst view

Analysts rate Fulcrum Therapeutics Inc a buy (3 buy, 3 hold, 1 sell out of 7) with an average price target of $5.83.

Shareholding

Insiders
3.35%
Institutions
114.11%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC8.60%
RA Capital Management, LLC7.93%
BlackRock Inc7.07%
TCG Crossover Management, LLC6.88%
BRAIDWELL LP4.11%
Nantahala Capital Management, LLC4.00%
Vanguard Capital Management, LLC3.53%
Siren, L.L.C.3.08%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Fulcrum Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.